
### FORM D

Notice of Exempt Offering of Securities

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



#### 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) ☐ None 0001516551 Load Guard Logistics, Inc. Name of Issuer Load Guard Transportation, Inc. Nemus Bioscience, Inc. LOAD GUARD Jurisdiction of LOGISTICS, INC. Incorporation/Organization LOAD GUARD NEVADA TRANSPORTATION, INC.

Entity	у Туре
•	Corporation
0	Limited Partnership
О	Limited Liability Company
О	General Partnership
0	Business Trust
0	Other

### Year of Incorporation/Organization

- Over Five Years Ago
- Within Last Five Years (Specify Year)
- Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer				
Nemus Bioscience, Inc.				
Street Address 1		Stree	et Address 2	
600 Anton Boulevard, Suite 1100	)			
City	State/Province/Countr	y	ZIP/Postal Code	Phone No. of Issuer
Costa Mesa	CALIFORNIA		92626	(949) 396-0330

## 3. Related Persons

Last Name	First Name	Middle Name
Berecz	Elizabeth	M.
Street Address 1	Street Address 2	
600 Anton Boulevard, Suite 1100		
City	State/Province/Country	ZIP/Postal Code
Costa Mesa	CALIFORNIA	92626
Relationship: Execut	ive Officer Director	Promoter

Clarification of Response (if Necessary)

Last Name	First Name		Middle Name
Murphy	Brian		<b>S</b> .
Street Address 1		Street Address 2	
600 Anton Boulevard, Suite 11	00		
City	State/Provinc	e/Country	ZIP/Postal Code
Costa Mesa	CALIFORN	ПА	92626
Relationship:	ecutive Officer	Director	Promoter

### Clarification of Response (if Necessary)

Last Name	First Name		Middle Name
Dhillon	Punit		
Street Address 1		Street Address 2	
600 Anton Boulevard, Suite 1	100		
City	State/Province/C	ountry	ZIP/Postal Code
Costa Mesa	CALIFORNIA		92626
Relationship:	xecutive Officer	Director	Promoter

Clarification of Response (if Necessary)

Last Name	First Name		Middle Name
Heppell	Jim		
Street Address 1		Street Address 2	
600 Anton Boulevard, Suite 1100			
City	State/Province/Cou	intry	ZIP/Postal Code
Costa Mesa	CALIFORNIA		92626
Relationship: Execut	ive Officer	Director	Promoter

Clarification of Response (if Necessary)

# 4. Industry Group

## C Agriculture

## Banking & Financial Services

- C Commercial Banking
- **C** Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund
- Other Banking & Financial C Services
- C Business Services

### Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas

5. Issuer Size **Revenue Range** 

No Revenues

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

C

C

C

C

C Other Energy

- C Retailing
- C Restaurants
  - Technology
  - C Computers
  - **C** Telecommunications
  - C Other Technology

### Travel

- C Airlines & Airports

### Aggregate Net Asset Value Range

- No Aggregate Net Asset Value
- O \$1 - \$5,000,000

## C

- C \$25,000,001 - \$50,000,000
- 0

  - \$5,000,001 \$25,000,000

- C Manufacturing **Real Estate** C Commercial
  - C Construction
  - C REITS & Finance
  - C Residential
  - C Other Real Estate

- Hospitals & Physicians

- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel
- C Other

C Other Health Care

Health Care

C

0

C Biotechnology

Health Insurance

Pharmaceuticals

- © \$25,000,001 \$100,000,000
- Over \$100,000,000
- O Decline to Disclose
- C Not Applicable

- C \$50,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
- C Not Applicable

6. Federal Exemption(s	and Exclusion(s)	Claimed (select all that				
apply)	, , , , , , , , , , , , , , , , , , , ,	·				
Rule 504(b)(1) (not (i), (ii)       Rule 505         Rule 504 (b)(1)(i)       Rule 506(b)         Rule 504 (b)(1)(ii)       Rule 506(c)         Rule 504 (b)(1)(iii)       Securities Act Section 4(a)(5)         Investment Company Act Section 3(c)						
	Investment Company	Act Section 3(c)				
7. Type of Filing						
New Notice Date of First Sale 2018-01-18						
Amendment						
8. Duration of Offering						
Does the Issuer intend this offering to la	st more than one year?	C Yes O No				
9. Type(s) of Securities Offered (select all that apply)						

	Pooled Investment Fund Interests	•	Equity
$\Box$	Tenant-in-Common Securities	•	Debt
	Mineral Property Securities	•	Option, Warrant or Other Right to Acquire Another Security
2	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transact	ion
Is this offering being made in connection with a business com transaction, such as a merger, acquisition or exchange offer?	bination C Yes © No
Clarification of Response (if Necessary)	
11. Minimum Investment	
Minimum investment accepted from any outside s	USD
12. Sales Compensation	
Recipient	ecipient CRD Number 🔲 None
(Associated) Broker or Dealer I None	(Associated) Broker or Dealer CRD 🔲 None

Interview     Indefinite     Interview     Interview <th>Street Address 1</th> <th>Street Address 2</th> <th></th>	Street Address 1	Street Address 2	
Interview     Indefinite     Interview     Interview <th></th> <th></th> <th></th>			
13. Offering and Sales Amounts         Fotal Offering Amount \$ 6800000       USD □ Indefinite         Fotal Amount Sold \$ 2400000       USD         Fotal Remaining to be \$ 4400000       USD □ Indefinite         Clarification of Response (if Necessary)       USD □ Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to	City	State/Province/Country	<b>ZIP/Postal Code</b>
13. Offering and Sales Amounts         Total Offering Amount \$ 6800000       USD □ Indefinite         Fotal Amount Sold \$ 2400000       USD         Total Remaining to be \$ 4400000       USD □ Indefinite         Clarification of Response (if Necessary)       USD □ Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to			
13. Offering and Sales Amounts         Fotal Offering Amount \$ 6800000       USD □ Indefinite         Fotal Amount Sold \$ 2400000       USD         Fotal Remaining to be \$ 4400000       USD □ Indefinite         Sold       USD □ Indefinite         Clarification of Response (if Necessary)       If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to	State(s) of Solicitation	□ All States	
Fotal Offering Amount       \$ 6800000       USD       Indefinite         Fotal Amount Sold       \$ 2400000       USD         Fotal Remaining to be       \$ 4400000       USD       Indefinite         Sold       USD       Indefinite         Clarification of Response (if Necessary)       USD       Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to       If the manual content in the total offering Amount and Total Remaining to			
Fotal Offering Amount       \$ 6800000       USD       Indefinite         Fotal Amount Sold       \$ 2400000       USD         Fotal Remaining to be       \$ 4400000       USD       Indefinite         Sold       USD       Indefinite         Clarification of Response (if Necessary)       USD       Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to       Indefinite			
Fotal Offering Amount       \$ 6800000       USD       Indefinite         Fotal Amount Sold       \$ 2400000       USD         Fotal Remaining to be       \$ 4400000       USD       Indefinite         Sold       USD       Indefinite         Clarification of Response (if Necessary)       USD       Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to       Indefinite			
Fotal Offering Amount       \$ 6800000       USD       Indefinite         Fotal Amount Sold       \$ 2400000       USD         Fotal Remaining to be       \$ 4400000       USD       Indefinite         Sold       USD       Indefinite         Clarification of Response (if Necessary)       USD       Indefinite         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to       If the manual content in the total offering Amount and Total Remaining to	13 Offering and Sales	Amounts	
Fotal Amount Sold       \$       2400000       USD         Fotal Remaining to be       \$       4400000       USD         Sold       USD       Indefinite         Clarification of Response (if Necessary)       If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to	ro. Onening and Oales	Amounto	
Total Amount Sold \$ 2400000 USD	Fotal Offering Amount \$ 6800000	USD 🗖 Indefinite	
Total Remaining to be       \$ 4400000       USD       Indefinite         Clarification of Response (if Necessary)         If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to		USD	
Clarification of Response (if Necessary) If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to	Fotal Romaining to be		
If the warrants are exercised in full, the company will receive aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to			
aggregate gross proceeds of \$3,400,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to	Clarification of Response (if Necessary	()	
amounts stated in Total Offering Amount and Total Remaining to			
	De Solu.		

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the

offering Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total

number of investors who already have invested in the offering:

		_
		•

1

## 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$ 0	USD	Estimate			
Finders' Fees	\$ 0	USD	Estimate			
Clarification of Response (if Necessary)						

## 16. Use of Proceeds

Γ

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state is such as the state in which the state in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains is principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Nemus Bioscience,	/s/ Elizabeth M.	Elizabeth M.	Chief Financial	2018-01-24
Inc.	Berecz	Berecz	Officer	